We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CRISPR Therapeutics AG | NASDAQ:CRSP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.31 | 2.35% | 57.02 | 57.03 | 57.07 | 58.75 | 56.39 | 57.93 | 1,077,464 | 19:59:30 |
By Ben Glickman
Shares of Bluebird bio fell after the company's sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor's treatment.
The stock was down 41% to $2.84 on Friday. Shares are down 60% this year.
The company's Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology.
The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug.
Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.
Evercore analysts said in a research note that the announcements gave Casgevy an advantage because of its lack of black-box label and lower price.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 08, 2023 15:56 ET (20:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year CRISPR Therapeutics Chart |
1 Month CRISPR Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions